Literature DB >> 1305632

Nocturnal plasma melatonin and alpha-melanocyte stimulating hormone levels during exacerbation of multiple sclerosis.

R Sandyk1, G I Awerbuch.   

Abstract

The pineal gland has been implicated recently in the pathogenesis of multiple sclerosis (MS). To investigate this hypothesis further, we studied nocturnal plasma melatonin levels and the presence or absence of pineal calcification (PC) on CT scan in a cohort of 25 patients (5 men, 20 women; mean age: 41.1 years; SD = 11.1; range: 27-72) who were admitted to a hospital Neurology service for exacerbation of symptoms. Plasma alpha-melanocyte stimulating hormone (alpha-MSH) estimations were included in the study since there is evidence for a feedback inhibition between alpha-MSH and melatonin secretion. Abnormal melatonin levels were found in 13 patients (52.0%), 11 of whom had nocturnal levels which were below the daytime values (i.e., < 25 pg/ml). Although melatonin levels were unrelated to the patient's age and sex, there was a positive correlation with age of onset of symptoms (p < .0001) and an inverse correlation with the duration of illness (p < .05). PC was noted in 24 of 25 patients (96%) underscoring the pathogenetic relationship between MS and the pineal gland. Alpha-MSH levels were undetectable in 15 patients (60.0%), low in two patients (8.0%), normal in seven patients (28.0%), and elevated in one patient (4.0%). Collectively, abnormal alpha-MSH levels were found in over 70% of patients. These findings support the hypothesis that MS may be associated with pineal failure and suggest, furthermore, that alterations in the secretion of alpha-MSH also occur during exacerbation of symptoms. The relevance of these findings to the pathogenesis of MS are discussed.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1305632     DOI: 10.3109/00207459208994783

Source DB:  PubMed          Journal:  Int J Neurosci        ISSN: 0020-7454            Impact factor:   2.292


  6 in total

Review 1.  The role of melatonin in Multiple Sclerosis.

Authors:  Charalampos Skarlis; Maria Anagnostouli
Journal:  Neurol Sci       Date:  2019-12-16       Impact factor: 3.307

2.  Biological effects of melatonin on osteoblast/osteoclast cocultures, bone, and quality of life: Implications of a role for MT2 melatonin receptors, MEK1/2, and MEK5 in melatonin-mediated osteoblastogenesis.

Authors:  Sifat Maria; Rebekah M Samsonraj; Fahima Munmun; Jessica Glas; Maria Silvestros; Mary P Kotlarczyk; Ryan Rylands; Amel Dudakovic; Andre J van Wijnen; Larry T Enderby; Holly Lassila; Bala Dodda; Vicki L Davis; Judy Balk; Matt Burow; Bruce A Bunnell; Paula A Witt-Enderby
Journal:  J Pineal Res       Date:  2018-01-17       Impact factor: 13.007

Review 3.  Association between seasonal factors and multiple sclerosis.

Authors:  Abdulla Watad; Shir Azrielant; Alessandra Soriano; Danielle Bracco; Arsalan Abu Much; Howard Amital
Journal:  Eur J Epidemiol       Date:  2016-05-25       Impact factor: 8.082

Review 4.  Demyelination in Multiple Sclerosis: Reprogramming Energy Metabolism and Potential PPARγ Agonist Treatment Approaches.

Authors:  Alexandre Vallée; Yves Lecarpentier; Rémy Guillevin; Jean-Noël Vallée
Journal:  Int J Mol Sci       Date:  2018-04-16       Impact factor: 5.923

Review 5.  Melatonin: buffering the immune system.

Authors:  Antonio Carrillo-Vico; Patricia J Lardone; Nuria Alvarez-Sánchez; Ana Rodríguez-Rodríguez; Juan M Guerrero
Journal:  Int J Mol Sci       Date:  2013-04-22       Impact factor: 5.923

6.  The role of melatonin in the pathogenesis of multiple sclerosis: a case-control study.

Authors:  Abbas Ghorbani; Mehri Salari; Vahid Shaygannejad; Rasul Norouzi
Journal:  Int J Prev Med       Date:  2013-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.